ClinicalTrials.gg
RecruitingNCT06999954SDS-GPSUpdated May 31, 2025

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

An observational study in Shwachman-Diamond Syndrome, SDS and IBMF, sponsored by Shwachman-Diamond Syndrome Alliance Inc. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Shwachman-Diamond Syndrome Alliance Inc · Observational

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8,000
Sex
All
01

Study summary

The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to

  • expand the understanding of SDS
  • improve the lives of people with SDS, and
  • accelerate the development of new therapies and cures for SDS.

By joining, participants will receive early access to relevant information about new clinical trials and other research opportunities (such as clinical registries) based on their profile, accelerating research and increasing clinical trial impact and recruitment success.

The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.

Read the detailed description

What is SDS-GPS?

The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, with the goal of

  • expanding the understanding of SDS and related conditions
  • improving the lives of people with SDS and related conditions, and
  • accelerating the development of new therapies and cures for SDS.

SDS-GPS was created for the patients, by the patients, with thoughtful input from patients, families, advocates, caregivers, researchers, clinicians, and regulators.

Participants will be part of a global community that cares, turns hope into action, and drives research. Participants' experience - whether it falls in the mild or severe end of the spectrum - matters. Their voice counts.

How can patients' stories help drive therapies and cures?

Participants' stories help paint a more complete picture of what SDS is and how it impacts the people living with it. Their participation helps build a strong, engaged community, which is critical to drive progress. Without patients and their families, research cannot advance.

The investigators (the SDS-GPS team at the SDS Alliance) use participants' de-identified aggregate survey responses and other data they share to develop a deeper understanding of the unmet needs of the community.

The investigators use the insights to

  • Prioritize research, educational resources, and community programming
  • Promote data and knowledge sharing via collaborations, publications, conference presentations, and other communication channels
  • Provide participants with information about relevant research opportunities (such as the SDS Registry and other natural history studies), clinical trials, educational resources, and community support connections.

What aspects of their story can participants share through SDS-GPS?

Surveys on the SDS-GPS Program Platform are designed to be quick and easy, without the need to have to look up any details from medical records. They can save their progress and come back anytime.

Survey topics include:

  • Socio-demographics
  • Medical history and diagnostics
  • Treatment and disease progression
  • Management of and access to care
  • Quality of life

How does SDS-GPS work?

  • Sign up for a free SDS-GPS account and enter a little bit about the participant. Enrolling and participating takes little time, and they can come back later to update any information.
  • Answer surveys from the comfort of their home at any time that works for them.
  • Privacy and security are protected to the highest standard.
  • Move research forward without any clinic visits or virtual appointments. With participants' consent, the investigators publish and share de-identified data (your survey responses) with approved researchers to support research to benefit the SDS community. The information participants provide through easy surveys is structured and coded behind the scenes, to be usable for high-quality, impactful research.
  • Keep track of the participants' medical appointments, medications, and symptoms via their SDS-GPS account, and have all the information at their fingertips whenever and wherever they need it.
  • Share any information participants like with their care team. Participants retain full control over access.

The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.

02

Conditions studied

  • Shwachman-Diamond Syndrome
  • SDS
  • IBMF
  • Congenital Neutropenia
  • Heme Malignancy
  • Shwachman Syndrome
  • Inherited Bone Marrow Failure
  • Exocrine Pancreatic Insufficiency
  • WHIM
  • ELANE
  • SBDS Gene Mutation
  • EFL1 Gene Mutation
  • DNAJC21 Gene Mutation
  • SRP54 Gene Mutation
  • Inherited Cancer Syndrome
  • Inherited Cancer-Predisposing Syndrome
  • Neutropenia, Severe Chronic
  • Neutropenia Other
  • Neutropenia Chronic Benign
  • Ribosome Alteration
  • Ribosomopathy
  • Immune Deficiency
  • Inherited BMF Syndrome
  • Inherited Immunodeficiency Diseases
  • Cognitive Delay, Mild
  • Myelodysplastic Syndromes
  • Pancytopenia

Keywords

  • Shwachman-Diamond Syndrome
  • Shwachman Diamond Syndrome
  • Shwachman Syndrome
  • SDS
  • IBMF
  • Inherited Bone Marrow Failure
  • Congenital Neutropenia
  • Immune Deficiency
  • SDS-like syndrome
  • genetic cancer predisposition
  • WHIM
  • ELANE
  • SBDS
  • EFL1
  • SRP54
  • DNAJC21
  • severe chronic neutropenia
  • exocrine pancreatic insufficiency
  • ribosomopathy
03

In context

Shwachman-Diamond Syndrome

21 studies on the registry are indexed under Shwachman-Diamond Syndrome; 4 are open to participants now.

Browse Shwachman-Diamond Syndrome studies →

Lead sponsor

This is the only study on the registry with Shwachman-Diamond Syndrome Alliance Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients and their caregivers may enroll from anywhere in the world using our online platform. Individuals for whom English is not their primary language may be enrolled with a translated informed consent form (and translated surveys if available). Currently available languages include English, Spanish, French, Italian, and German.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The Program invites patients of all ages who have a confirmed diagnosis of the below, using established diagnostic guidelines, plus their parents/caregivers.

  • Patients with a confirmed Shwachman-Diamond Syndrome (SDS) diagnosis, including a genetic or clinical diagnosis. The initial focus will be on patients with a genetic diagnosis of SDS based on biallelic mutations in SBDS or EFL1.
  • Patients with a confirmed diagnosis of an SDS-like syndrome (e.g. due to mutations in DNAJC21, SRP54, or other genes that may be associated with an SDS-like syndrome in the future).
  • Patients with other heritable hematological disorders (such as RUNX1-FPD, Fanconi Anemia) and/or congenital neutropenias (such as ELANE neutropenia) are also eligible for inclusion.
  • Caregivers, parents, and close relatives of all patients above, including of patients alive or deceased.

Exclusion criteria

Exclusion Criteria:

● People who do not meet the above criteria.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8,000 participants (estimated)
Target follow-up
120 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Patient (or caregiver) reported symptoms over time

    Patients report symptoms via surveys, grouped by organ system.

    Time frame: At baseline and every 12 months, prospectively.

  2. Genetics report uploaded by patient (or caregiver)

    Clinical genetics reports are uploaded by the patient (or caregiver) and curated by study staff to confirm a genetic diagnosis, understand variants, and assess the use of appropriate genetic testing methodologies.

    Time frame: Through study completion when the genetics report is available.

  3. Quality of life measures via PROMIS surveys

    PROMIS surveys in various domains, such as fatigue, pain, anxiety, and depression, are administered as surveys and scored with the standard PROMIS scoring methods. Specific PROMIS measures to include: v1.0 Anxiety 8a short form v1.0 Depression 8a short form v1.0 Pain Interference 6a short form v2.0 Cognitive Function 8a short form v1.0 Self-Efficacy for Managing Chronic Conditions: Manage Daily Activities 8a short form v1.0 - Self-Efficacy for Managing Symptoms 8a v2.0 Satisfaction Social Roles and Activities 8a short form v2.0 Ability to Part Social Roles and Activities 8a short form v2.0 Social Isolation 8a short form v1.0 Fatigue 13a short form (FACIT-Fatigue) v3.0 PP: Depressive Symptoms 6a short form v3.0 PP: Fatigue 10a short form v3.0 PP: Mobility 7a short form v3.0 PP: Pain Interference 8a short form v1.0 PP: Cognitive Function 7a short form

    Time frame: Through study completion, an average of 2-4 times per year.

  4. Patient reported burden of disease and treatment outcomes

    Patients fill out surveys to report on disease burden (such as number and duration of hospitalizations), treatment burden (such as surveillance), and treatment outcomes (such as HSC transplant outcomes)

    Time frame: At baseline and every 12 months, prospectively.

07

Study locations

1 of 1 sites recruiting
  • Shwachman-Diamond Syndrome Alliance Inc.
    Woburn, Massachusetts 01888, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This study is focused on patient reported data and findings will be published in the aggregate to safeguard patient personal health information.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06999954
Lead sponsor
Shwachman-Diamond Syndrome Alliance Inc
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Feb 7, 2024
Primary completion
Dec 2088 (estimated)
Completion
Dec 2088 (estimated)
Last update
May 31, 2025

Study contacts

Eszter Hars, Ph.D.
Contact
ehars@sdsalliance.org
6173291838
SDS-GPS Program Team
Contact
gps@sdsalliance.org
6173291838

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion